Oncology Radiopharmaceutical innovation: Giving cancer drugs second c... Molecular recycling could transform the economics and innovation of oncology drug discovery.
Oncology ESMO25: On radiopharmaceutical possibilities in oncology, wi... At ESMO 2025, pharmaphorum spoke with Dr Ebrahim Delpassand, CEO of RadioMedix.
Oncology ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs At ESMO, pharmaphorum spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.
News Sanofi, Orano cue up filings for GEP-NET radioligand therapy Clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings.
Oncology Advancing radiopharmaceutical development: Preclinical preci... Radiopharmaceutical development must move beyond fixed paradigms toward patient-specific, data-driven optimisation.
News Radiopharma CDMO Nucleus names former FDA boss as CEO CDMO Nucleus RadioPharma has a high-profile new CEO: former FDA Commissioner and veteran cancer researcher Dr Stephen Hahn.
R&D On genomics, NGS, and doing much more good than bad, with Ma... Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
